智通财经APP讯,药捷安康-B(02617)发布公告,根据恒生指数有限公司于2025年8月22日公布的恒生指数系列季度检讨结果,公司已获选并将纳入包括但不限于下述恒生指数系列成份股,自2025年9月8日起生效:
1.恒生综合指数;
2.恒生综合行业指数-医疗保健业;
3.恒生综合中小型股指数;
4.恒生综合小型股指数;
5.恒生医疗保健指数;
6.恒生创新药指数;
7.恒生港股通创新药指数;
8.恒生港股通创新药精选指数;及
9.恒生港股通药品及生物技术(可投资)指数。
公告称,公司获纳入恒生综合指数及上述指数反映投资者的认可度上升。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.